Maravai LifeSciences Holdings, Inc. (MRVI)
MRVI Stock Price Chart
Explore Maravai LifeSciences Holdings, Inc. interactive price chart. Choose custom timeframes to analyze MRVI price movements and trends.
MRVI Company Profile
Discover essential business fundamentals and corporate details for Maravai LifeSciences Holdings, Inc. (MRVI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Nov 2020
Employees
416.00
Website
https://www.maravai.comCEO
Bernd Brust
Description
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
MRVI Financial Timeline
Browse a chronological timeline of Maravai LifeSciences Holdings, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.05, while revenue estimate is $48.67m.
Earnings released on 7 May 2026
EPS came in at $0.01 surpassing the estimated -$0.05 by +120.00%, while revenue for the quarter reached $65.84m , beating expectations by +24.22%.
Earnings released on 25 Feb 2026
EPS came in at -$0.04 surpassing the estimated -$0.07 by +42.86%, while revenue for the quarter reached $49.87m , beating expectations by +1.67%.
Earnings released on 6 Nov 2025
EPS came in at -$0.08 falling short of the estimated -$0.06 by -33.33%, while revenue for the quarter reached $41.63m , missing expectations by -15.15%.
Earnings released on 11 Aug 2025
EPS came in at -$0.08 falling short of the estimated -$0.06 by -33.33%, while revenue for the quarter reached $47.40m , missing expectations by -5.36%.
Earnings released on 12 May 2025
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%, while revenue for the quarter reached $46.85m , beating expectations by +6.46%.
Earnings released on 18 Mar 2025
EPS came in at -$0.06 falling short of the estimated -$0.03 by -100.00%, while revenue for the quarter reached $56.41m , missing expectations by -2.39%.
Earnings released on 7 Nov 2024
EPS came in at -$0.02 falling short of the estimated -$0.01 by -150.00%, while revenue for the quarter reached $65.20m , beating expectations by +15.10%.
Earnings released on 7 Aug 2024
EPS came in at -$0.08 falling short of the estimated -$0.04 by -100.00%, while revenue for the quarter reached $73.40m , beating expectations by +2.47%.
Earnings released on 8 May 2024
EPS came in at -$0.02 falling short of the estimated -$0.02 by -21.43%, while revenue for the quarter reached $64.18m , beating expectations by +5.99%.
Earnings released on 22 Feb 2024
EPS came in at $0.01 surpassing the estimated $0.00 by +184.90%, while revenue for the quarter reached $74.14m , beating expectations by +15.16%.
Earnings released on 7 Nov 2023
EPS came in at -$0.01 falling short of the estimated -$0.00 by -257.14%, while revenue for the quarter reached $66.87m , missing expectations by -11.46%.
Earnings released on 7 Aug 2023
EPS came in at -$0.06 falling short of the estimated -$0.03 by -100.00%, while revenue for the quarter reached $68.91m , missing expectations by -3.12%.
Earnings released on 8 May 2023
EPS came in at $0.03 falling short of the estimated $0.04 by -17.24%, while revenue for the quarter reached $79.03m , missing expectations by -0.87%.
Earnings released on 22 Feb 2023
EPS came in at $0.35 surpassing the estimated $0.34 by +2.94%, while revenue for the quarter reached $204.71m , missing expectations by -0.10%.
Earnings released on 2 Nov 2022
EPS came in at $0.37 surpassing the estimated $0.32 by +15.62%, while revenue for the quarter reached $191.26m , missing expectations by -1.97%.
Earnings released on 4 Aug 2022
EPS came in at $0.54 surpassing the estimated $0.45 by +20.00%, while revenue for the quarter reached $242.73m , beating expectations by +4.08%.
Earnings released on 5 May 2022
EPS came in at $0.54 surpassing the estimated $0.44 by +22.73%, while revenue for the quarter reached $244.29m , beating expectations by +5.17%.
Earnings released on 23 Feb 2022
EPS came in at $0.45 surpassing the estimated $0.38 by +18.42%, while revenue for the quarter reached $228.44m , beating expectations by +9.78%.
Earnings released on 10 Nov 2021
EPS came in at $0.44 surpassing the estimated $0.35 by +25.71%, while revenue for the quarter reached $204.81m , beating expectations by +34.62%.
Earnings released on 10 Aug 2021
EPS came in at $0.44 surpassing the estimated $0.32 by +37.50%, while revenue for the quarter reached $217.78m , beating expectations by +11.79%.
MRVI Stock Performance
Access detailed MRVI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
